Summary
BeOne Medicines Ltd. (ONC), now operating as BeiGene, Ltd., filed an 8-K on August 11, 2017, to announce a significant public offering of American Depositary Shares (ADSs). The company entered into an Underwriting Agreement with a syndicate of underwriters led by Morgan Stanley & Co. LLC, Goldman Sachs & Co. LLC, and Cowen and Company, LLC. This offering involved 2,465,000 ADSs priced at $71.00 per ADS, with an option for underwriters to purchase an additional 369,750 ADSs. The company anticipates net proceeds of approximately $164.1 million, potentially reaching $188.7 million if the overallotment option is fully exercised. The net proceeds are earmarked for working capital, general corporate purposes, and crucially, research and development activities. This capital infusion is a key development for investors, signaling the company's commitment to advancing its pipeline. The offering is expected to close on August 16, 2017, subject to standard closing conditions. The filing also includes customary representations, warranties, and indemnification clauses related to the offering, made under an effective shelf registration statement on Form S-3.
Key Highlights
- 1BeiGene, Ltd. priced a public offering of 2,465,000 American Depositary Shares (ADSs) at $71.00 per ADS.
- 2The offering is expected to generate approximately $164.1 million in net proceeds, with potential for up to $188.7 million if the underwriters fully exercise their option to purchase additional ADSs.
- 3Proceeds are intended for working capital, general corporate purposes, and research and development (R&D) activities.
- 4The Underwriting Agreement was executed on August 10, 2017, with Morgan Stanley, Goldman Sachs, and Cowen as lead underwriters.
- 5The offering is scheduled to close on August 16, 2017, contingent upon customary closing conditions.
- 6The offering was made under the company's effective shelf registration statement on Form S-3.
- 7The company also issued a press release on August 10, 2017, announcing the pricing of the offering.